Diabetic Retinopathy Program
Diabetic Retinopathy
Key Facts
About Lxbio Pharmaceuticals
Lxbio Pharmaceuticals is an emerging, private biotech company based in Lisbon, Portugal, operating in the high-growth sectors of antibody and bacteriophage therapies. It is developing a pre-clinical pipeline targeting therapeutic areas with significant unmet needs, including diabetic foot infections, ocular surface infections, atopic dermatitis, respiratory infections, and diabetic retinopathy. The company has made strategic infrastructure investments, inaugurating a dedicated biologics R&D and production unit, and is actively seeking investment to advance its innovative platforms and pipeline programs.
View full company profileAbout Novaliq
Novaliq is a private, clinical-stage biotech pioneering a novel, water-free drug delivery platform (EyeSol®) for ophthalmology. Its technology is designed to enhance drug bioavailability, retention time, and tolerability on the ocular surface. The company has achieved its first commercial approvals in the US for dry eye disease (NOV03, CyclASol) and is advancing a pipeline targeting glaucoma, diabetic retinopathy, dermatology, and uveitis. With a seasoned management team and strategic partnerships, Novaliq is positioned to challenge the standard of care in topical ocular therapeutics.
View full company profileTherapeutic Areas
Other Diabetic Retinopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program (DR) | Cloudbreak Pharmaceutical | Pre-clinical / Clinical |
| NOX4 Inhibitor (GLX7013114) | Glucox Biotech | Preclinical |
| PER-001 | Perfuse Therapeutics | Phase 2 |
| jCell (RPCs) | jCyte | Preclinical |
| LumineticsCore | Digital Diagnostics | Approved |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical |
| NBP-14 and derivatives | Neuro Bio | Research |
| Vasculogenic Cell Therapy | Vascugen | Pre-clinical |
| Danegaptide | Breye Therapeutics | Phase 2 |
| OcuRetina | Oculotix | Phase 2 |
| YH14618 | Yuhan | Phase 2 |